OctoPlus announces 2011 first half-year results
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the specialty
pharmaceutical company, announces today its results for the six-month period
ended 30 June 2011.
Highlights first half-year 2011
1. Drug delivery technology commercialisation
* Full development of our newly signed agreement with ESBATech, a subsidiary
of Alcon/Novartis has started. This is our first project in ophthalmology
(eye care). Injections into the eye are an area where the benefits of
reduced injection frequency are obvious.
* We signed a new drug delivery evaluation contract with a top-10
biopharmaceutical company in April.
* Revenues from projects based on our proprietary drug delivery technology
continue to grow.
2. Locteron
* Successful final results of Phase IIb clinical study demonstrated Locteron's
superior profile in terms of significantly reduced side effects and improved
convenience, further strengthening our confidence in the potential of this
best-in-class hepatitis C product.
* Biolex has announced that Phase III studies are planned to commence in
2012.
* We expect to play an active role in the preparation of the next clinical
phase.
3. Contract formulation and manufacturing services
* We signed service contracts with three new clients including a new process
development and manufacturing contract which was announced in July.
* Net bookings (signed new work minus cancellations) in the first half-year of
2011 increased by 20% versus prior year.
* Non-Locteron revenues increased compared to the same period last year as a
result of our strengthened order book.
* OctoPlus has now worked for more than 125 companies including half of the
top 10 pharmaceutical companies worldwide.
Financial results
* Non-Locteron service revenues increased by 18% to ? 3.8 million (2010: ?
3.2 million).
* Total revenues decreased by 2% to ? 4.0 million (2010: ? 4.0 million) driven
by lower revenues from Locteron, which were ? 0.1 million (2010: ? 0.6
million).
* Total costs (including interest) further reduced by 10% to ? 6.8 million
(2010: ? 7.6 million) as a result of continued cost control.
* Net loss reduced by 19% to ? 2.9 million (2010: net loss of ? 3.5 million).
* Cash outflow of ? 1.5 million (2010: cash outflow ? 2.9 million) resulted in
a cash position of ? 1.2 million at 30 June 2011 (? 0.4 million last year).
* A ? 2.0 million credit line facility is in place with ABN Amro Bank, of
which ? 0.9 million was available per 30 June 2011.
Outlook
We continue to focus on strengthening our portfolio including a well-balanced
mix of "fee for service" projects and longer-term contracts where we retain
upside in the form of royalties and milestones. In addition, we will continue to
focus on cost control.
Jan Egberts, M.D., CEO of OctoPlus comments: "In the first six months of my time
at OctoPlus we have dedicated a significant amount of time on improving
operational efficiency, streamlining organisational structure and maintaining
our reduced cost base. During this period I travelled extensively to both
existing and new customers. Our team has identified a number of high-value
opportunities in specialty generics, where we can co-invest and leverage our
world-class expertise in formulation development. Our acquisition pipeline is
slowly re-emerging but due to difficult market conditions our lead time in
closing deals has increased over the past year. During the remainder of the year
we will also look for other ways to strengthen our balance sheet. Finally, we
look forward to participate in the Phase III clinical development for Locteron.
We expect our focus and dedication to pay off in the periods to follow."
Conference call and webcast presentation
OctoPlus will hold a conference call and webcast presentation today at 10:00 AM
CET. This event can also be followed live via OctoPlus' website www.octoplus.nl.
If you would like to participate in the conference call, please dial in on
telephone number +31 (0) 45 631 6902. After the presentation, Jan Egberts, CEO
of OctoPlus, and Susan Swarte, CFO, will be available to answer questions. After
the event, the webcast will be available for replay on the Company's website.
Contact
For further information, please contact: Rianne Roukema, Corporate
Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor
Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our technology is Locteron®,
a controlled release formulation of interferon alpha for the treatment of
chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October
2008. Locteron is being manufactured for Biolex by OctoPlus and has recently
completed Phase IIb clinical studies with superior clinical data versus current
treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the full press release including financial tables:
http://hugin.info/137076/R/1534705/467811.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1534705]
Unternehmensinformation / Kurzprofil:
Datum: 29.07.2011 - 07:32 Uhr
Sprache: Deutsch
News-ID 56824
Anzahl Zeichen: 8405
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus announces 2011 first half-year results"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
